An In Vitro Pre-Clinical MPS Model for Metabolic Associated Steatohepatitis for Drug Efficacy

Explore a 28-minute webinar presented by Christiana Skarlatopoulou, a Scientist at CN Bio, focusing on an in vitro pre-clinical microphysiological system (MPS) model for metabolic associated steatohepatitis (NASH) and drug efficacy testing. Gain insights into the global epidemic of non-alcoholic fatty liver disease (NAFLD) and its progression to NASH, characterized by lipid accumulation, immune cell infiltration, and liver fibrosis. Discover why current preclinical models, primarily animal-based, fail to adequately predict clinical outcomes for NASH treatments. Learn about the urgent need for improved preclinical NASH models and how organ-on-a-chip technology offers a promising alternative method to bridge the gap between preclinical predictions and clinical results. Understand the potential of MPS in revolutionizing drug efficacy testing for NASH and other liver diseases.

An In Vitro Pre-Clinical MPS Model for Metabolic Associated Steatohepatitis for Drug Efficacy